红细胞生成
医学
贫血
骨髓增生异常综合症
造血
无效红细胞生成
重症监护医学
生物信息学
机制(生物学)
海西定
免疫学
生活质量(医疗保健)
疾病
促红细胞生成素
红细胞
干细胞
临床试验
治疗方法
细胞
输血
临床实习
再生障碍性贫血
血细胞
作者
Vera Ademà,Francesco Pesce,Guillermo Garcia‐Manero,Valeria Santini,Simona Colla
标识
DOI:10.1158/2643-3230.bcd-25-0393
摘要
Minimizing the transfusion burden is one of the primary clinical goals for most patients with myelodysplastic syndromes (MDS), which are incurable hematopoietic stem cell neoplasms. In some patients, supportive red blood cell transfusions can lead to clinical improvement, but frequent transfusions induce iron overload, which can have detrimental effects on cardiac and hepatic function, affect patients' quality of life, and incur additional healthcare costs. In this review, we summarize how erythropoiesis is regulated under steady-state conditions, dissect the molecular mechanisms underlying anemia in MDS, and review therapeutic approaches to overcome ineffective erythropoiesis in patients with these diseases. SIGNIFICANCE: A better understanding of the biological mechanisms underlying anemia in MDS is needed to develop targeted therapies for a personalized treatment approach. Anemia, a hallmark of MDS, highly affects patients' quality of life and contributes to overall morbidity. Current knowledge of the mechanisms of action of the available drugs targeting anemia in MDS is limited.
科研通智能强力驱动
Strongly Powered by AbleSci AI